Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ching C Lau

Showing results (111-120 of 117) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 117 results.
Nature|June 23, 2012
Novel mutations target distinct subgroups of medulloblastomaGiles Robinson, Matthew Parker, Tanya A Kranenburg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2015
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled TrialStefan S Bielack, Sigbjørn Smeland, Jeremy S Whelan, et al.
Cell|January 30, 2016
Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse GliomaMichele Ceccarelli, Floris P Barthel, Tathiane M Malta, et al.
European Journal of Cancer (Oxford, England : 1990)|January 28, 2019
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohortSigbjørn Smeland, Stefan S Bielack, Jeremy Whelan, et al.
Acta Neuropathologica|May 21, 2014
CNS-PNETs with C19MC amplification and/or LIN28 expression comprise a distinct histogenetic diagnostic and therapeutic entityTara Spence, Patrick Sin-Chan, Daniel Picard, et al.
The Lancet. Oncology|August 30, 2016
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trialNeyssa M Marina, Sigbjørn Smeland, Stefan S Bielack, et al.
Human Molecular Genetics|July 17, 2014
Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33Zhaoming Wang, Bin Zhu, Mingfeng Zhang, et al.
Pageof 12

Showing results (111-120 of 117) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 117 results.
Nature|June 23, 2012
Novel mutations target distinct subgroups of medulloblastomaGiles Robinson, Matthew Parker, Tanya A Kranenburg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2015
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled TrialStefan S Bielack, Sigbjørn Smeland, Jeremy S Whelan, et al.
Cell|January 30, 2016
Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse GliomaMichele Ceccarelli, Floris P Barthel, Tathiane M Malta, et al.
European Journal of Cancer (Oxford, England : 1990)|January 28, 2019
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohortSigbjørn Smeland, Stefan S Bielack, Jeremy Whelan, et al.
Acta Neuropathologica|May 21, 2014
CNS-PNETs with C19MC amplification and/or LIN28 expression comprise a distinct histogenetic diagnostic and therapeutic entityTara Spence, Patrick Sin-Chan, Daniel Picard, et al.
The Lancet. Oncology|August 30, 2016
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trialNeyssa M Marina, Sigbjørn Smeland, Stefan S Bielack, et al.
Human Molecular Genetics|July 17, 2014
Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33Zhaoming Wang, Bin Zhu, Mingfeng Zhang, et al.
Pageof 12